Evaluate the Effect of Exenatide Treatment on Coronary Artery Endothelial Function

NCT02584075 · Unknown status

Last updated 2026-05-28

This clinical trial tests whether the medication exenatide can improve the function of the coronary arteries in people with coronary endothelial dysfunction.

Status Unknown status The sponsor has not confirmed the status recently.

Phase Phase 4 Monitors a drug already on the market.

Type Interventional (clinical trial)

Design open-label (no blinding) treatment study

Participants 100 people Planned (estimated).

Who can join Ages 20–65 · all sexes

Timeline Started 2015-11 · est. completion 2018-01

What this study is testing ClinicalTrials.gov NCT02584075 ↗

Description as written by the study sponsor.

Type 2 diabetes mellitus (T2DM) is an important risk factor of cardio-cerebral vascular disease such as coronary heart disease. GLP-1 is a kind of incretin secreted by the L-cell located in Ileum. It acts as an incretin hormone by protentiating glucose-stimulated insulin release. Recent studies reported that GLP-1 RA can protect the vascular endothelial and prevent vascular from atherosclerosis. Investigators design this study to investigate exenatide's effect on the improvement of the coronary endothelial function by evaluating endothelium dependent diastolic function and testing the vascular endothelial active substance and related inflammatory factors.

Treatments tested

Byetta (Exenatide) Drug

Exenatide treatment: 5 µg twice/day subcutaneous injection for 4 weeks, 10 µg twice/day subcutaneous injection for 8 weeks.
Glucophage ( Metformin Hydrochloride) Drug

Metformin 500mg Tid

Main thing measured	Coronary endothelial function
Sponsor	Beijing Chao Yang Hospital
Conditions studied	Coronary Endothelial Function
GLP-1 drugs	exenatide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT02584075 ↗